Australian Government - Department of Health and Ageing

Medical Services Advisory Committee (MSAC)

Reference 9a

Nucleic Acid Amplification (NAA) testing in haemotological malignancy

Nucleic Acid Amplification (NAA) testing in haemotological malignancy



REFERENCE 09a (i)
Polymerase chain reaction (PCR) in the diagnosis and monitoring of chronic myeloid leukemia (CML)

REFERENCE 09a (ii)
Polymerase chain reaction (PCR) in the diagnosis and monitoring of acute promyelocytic leukemia (APL)

REFERENCE 09a (iii)
Polymerase chain reaction (PCR) in the diagnosis and monitroing of acute myeloid leukemia (AML)

REFERENCE 09a (iv)
Polymerase chain reaction (PCR) in the diagnosis and monitoring of acute lymphoblastic leukemia (ALL)



Reference No.9a (incorporates i, ii, iii and iv)
Reference NameNucleic Acid Amplification (NAA) testing in haemotological malignancy
Advisory PanelsProfessor Sydney Bell
(Chair and MSAC member)
Dr Paul Craft
(MSAC member)
Dr John Primrose
(Medical Advisor to the MSAC until February 2002)
Associate Professor Mark Hertzberg
(Haemotology Society of Australia and New Zealand nominee)
Associate Professor Harry Iland
(co-opted member)
Dr Paula Marlton
(Royal College of Pathologists of Australasia nominee)
Mr Michael Ralston
(Pathology Services Table Committee)
Date Received by MSAC Secretariat1 October 2000
Stage 1 - EligibilityEligible
Stage 2 - AssessmentCompleted
Stage 3 - Formulation of Advice to the MinisterThe MSAC recommended that on the strength of evidence pertaining to safety, effectiveness and cost-effectiveness of nucleic acid amplification testing in haemotological malignancies public funding should be supported for this procedure
Stage 4 - DecisionEndorsed by the Minister for Health and Ageing 22 June 2004
Stage 5 - ImplementationImplemented